Jhansi Kompala

Jhansi Kompala

Auto-generated profile, based on publicly available information

Jhansi Kompala

IonCure Tech

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SDShreya Das
Shreya Das
GGGorky Guha
Gorky Guha
SKSohith Reddy Korlagunta
Sohith Reddy Korlagunta
JKJhansi Kompala
Jhansi Kompala
SBShree Deepti Biyagudem
Shree Deepti Biyagudem
ABAbhijit G. Banerjee
Abhijit G. Banerjee
Emodin is a naturally occurring anthraquinone and has been of great interest as a multi-target anticancer agent with potential anti-metastatic effects. There is a growing body of evidence that emodin inhibits the progression of cancer by regulating essential events of epithelial–mesenchymal transition (EMT) and extracellular matrix remodeling. It suppresses matrix metalloproteinases and other associated proteolytic enzymes, thus hindering tumor invasion and metastatic spread. Emodin also suppresses key EMT-related transcription factors, such as Snail, Slug and Twist resulting in lower expression of mesenchymal markers, recovery of epithelial phenotype and lack of cellular motility. These effects are mechanistically mediated by disrupting central oncogenic pathways including transforming growth factor-β (TGF-β)/Smad, Akt/mTOR, MAPK and other signaling pathways that promote EMT plasticity. Recent research also indicates that emodin has a role in regulating cytoskeletal organization, ROS signal, and interactions with the tumor microenvironment that promote metastatic behavior. Although there is strong preclinical evidence, there are still a number of translational gaps. This limits its possible therapeutic use due to low bioavailability, low stability, and inconsistent tumor responsiveness. Possible resistance mechanisms, such as the compensatory activation of other pathways such as Wnt/ β-catenin and survival signaling cascades, are not sufficiently characterized. There is also lack of clinical validation with few controlled trials assessing safety and anti-metastatic efficacy across different types of cancer. The future directions are to focus on optimization of formulation and delivery, improvement of the pharmacokinetics, patient stratification, biomarker-based guided, and rigorous comparisons of combination regimens with chemotherapy, radiotherapy, and targeted agents. These approaches can be used to achieve the full potential of emodin as a therapeutic candidate, which is a metastasis-modulating agent.
1

13 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KRK. Sohith Reddy
K. Sohith Reddy
KJKompala Jhansi
Kompala Jhansi
MKMohammad Saddam Khan
Mohammad Saddam Khan
BRBrooks Robinson
Brooks Robinson
KHKhushi
Khushi
SKSukant Khurana
Sukant Khurana
GCC countries are experiencing a rapid demographic transition. Life expectancy at birth has increased to between 76-80 years, and the elderly population is expected to double by 2050. This demographic transition is accompanied by a growing burden of neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, placing increasing demands on health and social care systems. This study examines three interconnected dimensions of the crisis: awareness of neurodegeneration among older people, the infrastructure and human capacity of care systems and the existing gaps that media, technology and community institutions might be able to bridge. Studies show that cognitive decline is frequently viewed as a natural consequence of aging rather than as a medical disorder that requires diagnosis and treatment. Limited health literacy, culturally constructed perceptions of health and illness, and use of informal support mechanisms, including family, religious, and community elders, could all be factors that influence the decision to seek health care. Stigma, limited awareness, and concerns about seeking institutional care may contribute to delays in diagnosis and treatment. On the care side, where families provide a substantial proportion of support for older adults, the region faces shortages of specialized professionals, including neurologists and geriatricians. Available care models are often fragmented and insufficiently integrated, while formal caregiver training and support remain limited in many settings, contributing to the burden on families. These results suggest that there may be room to enhance screening, referrals, and health literacy through increased coverage by mainstream media, collaborations with religious and community organizations, and broader implementation of telemedicine. Drawing on selected international examples from Japan, Sweden, Australia, and the United Kingdom, the paper proposes a multi-part policy framework comprising a national awareness campaign, strengthening of the geriatric healthcare workforce, a care provider certificate program, and digital health. The paper underlines the need for culturally appropriate, collaborative action to build more integrated and person-centered neurodegenerative care systems throughout the GCC.

21 April 2026 in Cambridge Open Engage
Verified
Preprint
Open access
PDF file
SDShreya Das
Shreya Das
ADAditi Dubey
Aditi Dubey
KLKyle Laney
Kyle Laney
JKJhansi Kompala
Jhansi Kompala
JSJasmine Steffi
Jasmine Steffi
ABAbhijit G. Banerjee
Abhijit G. Banerjee
Angiogenesis is central to tumor development and metastasis because it facilitates oxygen and nutrient supplies to cancer cells. Inhibiting angiogenic pathways is a commonly used strategy in the treatment of cancer, usually through inhibitory actions that first determine targeted apoptosis of the key proangiogenic factor, vascular endothelial growth factor (VEGF), and its upstream regulator, hypoxia-inducible factor 1-alpha (HIF-1α). Emodin, a common anthraquinone derivative of natural origins, has a variety of actions to inhibit angiogenesis, which include the ability to inhibit the expression of VEGF, as well as the ability to reverse stabilization of HIF-1α and inhibit tumor microvessel branching. Moreover, emodin is recognized for pathways other than those involving VEGF, such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), which impact endothelial cell proliferation and pericyte recruitment. Emodin can facilitate vessel destabilization by acting on several angiopoietins, causing the function of the tumor vasculature to be disrupted. Molecular docking studies have shown emodin can bind the ATP-binding pocket of VEGFR-2 and the degradation domain of HIF-1α, acting as a multi-target inhibitory compound. These mechanisms collectively obstruct tumor vascularization, deprive tumor cells of vital nutrients, and prevent cancer progression. Pre-clinical studies to date have determined it to be a significant anti-angiogenic agent and a synergistic agent in combination with chemotherapy and/or targeted therapies that can be given to patients. Future studies will address bioavailability issues, target the associated resistance mechanisms, and explore ways to increase its efficacy as an adjuvant in cancer treatment.
1

25 April 2026 in Cambridge Open Engage
Verified
Preprint
Open access
PDF file
SDShreya Das
Shreya Das
ADAditi Dubey
Aditi Dubey
KLKyle Laney
Kyle Laney
JKJhansi Kompala
Jhansi Kompala
JAJasmine Stefii A
Jasmine Stefii A
ABAbhijit G. Banerjee
Abhijit G. Banerjee
Angiogenesis is central to tumor development and metastasis because it facilitates oxygen and nutrient supplies to cancer cells. Inhibiting angiogenic pathways is a commonly used strategy in the treatment of cancer, usually through inhibitory actions that first determine targeted apoptosis of the key proangiogenic factor, vascular endothelial growth factor (VEGF), and its upstream regulator, hypoxia-inducible factor 1-alpha (HIF-1α). Emodin, a common anthraquinone derivative of natural origins, has a variety of actions to inhibit angiogenesis, which include the ability to inhibit the expression of VEGF, as well as the ability to reverse stabilization of HIF-1α and inhibit tumor microvessel branching. Moreover, emodin is recognized for pathways other than those involving VEGF, such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), which impact endothelial cell proliferation and pericyte recruitment. Emodin can facilitate vessel destabilization by acting on several angiopoietins, causing the function of the tumor vasculature to be disrupted. Molecular docking studies have shown emodin can bind the ATP-binding pocket of VEGFR-2 and the degradation domain of HIF-1α, acting as a multi-target inhibitory compound. These mechanisms collectively obstruct tumor vascularization, deprive tumor cells of vital nutrients, and prevent cancer progression. Pre-clinical studies to date have determined it to be a significant anti-angiogenic agent and a synergistic agent in combination with chemotherapy and/or targeted therapies that can be given to patients. Future studies will address bioavailability issues, target the associated resistance mechanisms, and explore ways to increase its efficacy as an adjuvant in cancer treatment.